PASG · Passage BIO, Inc. · Executive Compensation
$4.86
-0.14 (-2.80%)
At close · Sep 14
Going-concern doubt
— flagged Aug 10, 2026
Substantial doubt about the company's ability to continue as a going concern.
“As a result, there is substantial doubt about the Company's ability to continue as a going concern within one year after the date that these consolidated financial statements are issued.”View the 10-Q filed Aug 10, 2026
Market Cap
$16.09M
Shares
3.22M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Athena Countouriotis | member of the Audit Committee | Appointed | 2025-09-18 |
| Saqib Islam | member of the Board of Directors | Resigned | 2025-09-18 |
| Thomas Kassberg | Class I director and as a member of the Audit Committee of the Board | Appointed | 2024-09-10 |
| Susan Browne, Ph.D. | Chief Scientific Officer | Appointed | 2024-08-01 |
| Stuart Henderson | Chief Business Officer | Appointed | 2024-08-01 |
| Mark Forman, M.D., Ph.D. | Chief Medical Officer | Resigned | 2024-08-01 |